Inhibikase Therapeutics is a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Co.'s multi-therapeutic pipeline has a primary focus on neurodegeneration and its primary program utilizing IkT-148009, c-Abl inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases. Co. is also developing platform technologies for alternate ways to deliver protein kinase inhibitors in patients.
|
Free IKT Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Strong Buy (4.00 out of 4) 89th percentile
(ranked higher than approx. 89% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |